OKYO Pharma Ltd

OKYOReported to SECin USCIK 0001849296Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 14. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 14
Form 4 lines at OKYO Pharma Ltd, most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
BRANCACCIO JOHN P—Open-market buy$7,3855,000 sharesAug 7, 2026BRANCACCIO JOHN P$7,385Buy · Aug 7Open-market buy5,000Aug 7, 2026
Dempsey Robert JohnCHIEF EXECUTIVE OFFICEROpen-market buy$23,08515,000 sharesAug 7, 2026Dempsey Robert JohnCHIEF EXECUTIVE OFFICER$23,085Buy · Aug 7Open-market buy15,000Aug 7, 2026
JACOB GARY SCHIEF DEVELOPMENT OFFICEROpen-market buy$4,9003,500 sharesAug 7, 2026JACOB GARY SCHIEF DEVELOPMENT OFFICER$4,900Buy · Aug 7Open-market buy3,500Aug 7, 2026
CERRONE GABRIELE M—Open-market buy$35,00025,000 sharesAug 7, 2026CERRONE GABRIELE M$35,000Buy · Aug 7Open-market buy25,000Aug 7, 2026
Patil Rajkumar V.Chief Scientific OfficerOpen-market buy$5,0113,363 sharesAug 7, 2026Patil Rajkumar V.Chief Scientific Officer$5,011Buy · Aug 7Open-market buy3,363Aug 7, 2026